US Hemp Product Industry ‘Dying On Vine’ Without Lawful Use Legislation Or Enforcement Guidance
FDA’s tolerance of sales of hemp-containing supplements isn’t the assurance industry needs for investing in development of ingredients and products which have been shown to provide various health benefits.
You may also be interested in...
Absence of hemp provisions in House bill could be a problem with Senate Democrats, who have drafted legislation not only on producing, marketing and possessing marijuana but also using in supplements ingredients classified as hemp. Still, Senate passage of cannabis legalization is unlikely.
In report explaining congressional intent for omnibus spending bill, House and Senate appropriators note concerns about, and target $5m for, regulation of supplement market. Question on moving drug ingredients from Rx to nonprescription not accompanied by targeted funding.
Among four FDA regulatory items withdrawn from OMB review is “Cannabidiol Enforcement Policy; Draft Guidance for Industry,” which the agency submitted in July 2020.